<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="82420"><DrugName>bitespiramycin (oral tablet, bacterial infection), Shenyang Tonglian Group/Institute of Medicinal Biotechnology CAMS</DrugName><DrugSynonyms><Name><Value>bitespiramycin (oral tablet, bacterial infection), Shenyang Tonglian Group/Institute of Medicinal Biotechnology CAMS</Value></Name><Name><Value>bitespiramycin</Value></Name><Name><Value>biotechspiramycin</Value></Name><Name><Value>carrimycin</Value></Name><Name><Value>isovalerylspiramycin I</Value></Name><Name><Value>isovalerylspiramycin II</Value></Name><Name><Value>isovalerylspiramycin III</Value></Name><Name><Value>kelimeisu</Value></Name></DrugSynonyms><CompanyOriginator id="1012170">Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences</CompanyOriginator><CompaniesPrimary><Company id="1064862">Shenyang Tonglian Group Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="1012170">Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1012170" type="Company"><TargetEntity id="5035524656" type="organizationId">Institue of Medicinal Biotechnology Academy of Medical Sciences &amp; Peking Union Medical College</TargetEntity></SourceEntity><SourceEntity id="1064862" type="Company"><TargetEntity id="5036353887" type="organizationId">Shenyang Tonglian Group Co Ltd</TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"/><TargetEntity id="10060945" type="MEDDRA"/><TargetEntity id="D001424" type="MeSH"/><TargetEntity id="-1693440076" type="omicsDisease"/><TargetEntity id="800" type="siCondition"/></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="PR">Pre-registration</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="40">Bacterial infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="1594">Antibacterial</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-06-01T02:59:07.000Z</LastModificationDate><ChangeDateLast>2018-06-02T00:00:00.000Z</ChangeDateLast><AddedDate>2012-12-18T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1064862" linkType="Company"&gt;Shenyang Tonglian Group&lt;/ulink&gt;, under license from &lt;ulink linkID="1012170" linkType="Company"&gt;Institute of Medicinal Biotechnology&lt;/ulink&gt;, is developing an oral tablet formulation of bitespiramycin (biotechspiramycin; carrimycin; shengjimycin; kelimeisu) for the potential treatment of bacterial infection [&lt;ulink linkID="1996914" linkType="Reference"&gt;1996914&lt;/ulink&gt;]. In September 2010, an NDA was submitted to the SFDA [&lt;ulink linkID="1584695" linkType="Reference"&gt;1584695&lt;/ulink&gt;]; in November 2016, review of the application was concluded [&lt;ulink linkID="1894213" linkType="Reference"&gt;1894213&lt;/ulink&gt;]. In January 2018, another launch application was filed in China [&lt;ulink linkID="1996915" linkType="Reference"&gt;1996915&lt;/ulink&gt;]; in March 2018, the application was granted Priority Review in China [&lt;ulink linkID="2017900" linkType="Reference"&gt;2017900&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In September 2010, an NDA was submitted to the SFDA as a class 1.1 chemical drug and the application was  listed as "National Science and Technology Major Project" [&lt;ulink linkID="1350763" linkType="Reference"&gt;1350763&lt;/ulink&gt;], [&lt;ulink linkID="1976493" linkType="Reference"&gt;1976493&lt;/ulink&gt;]. In December 2012, supplemental materials were required by the SFDA to conclude the review [&lt;ulink linkID="1384044" linkType="Reference"&gt;1384044&lt;/ulink&gt;]. In November 2016, review of the application was concluded, but the outcome was not published at that time [&lt;ulink linkID="1894213" linkType="Reference"&gt;1894213&lt;/ulink&gt;]. In January 2018, another launch application of the tablet as a class 1 chemical drug was filed in China [&lt;ulink linkID="1996915" linkType="Reference"&gt;1996915&lt;/ulink&gt;]; in March 2018, the application was granted Priority Review in China [&lt;ulink linkID="2017900" linkType="Reference"&gt;2017900&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By August 2017, published data had shown that in vitro activities of bitespriamycin (BT) were similar to those of &lt;ulink linkID="2587" linkType="Drug"&gt;azithromycin&lt;/ulink&gt; (AZM) but were more effective than those of acetylspiramycin (AT-SP) against Chlamydia trachomatis (Ct), Chlamydia pneumoniae (Cp), Ureaplasma urealyticum (Uu), and Mycoplasma pneumoniae (Mp). BT had similar efficacy to AZM in the treatment of Mp infection in a hamster model at the same clinically recommended doses [&lt;ulink linkID="2040283" linkType="Reference"&gt;2040283&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Bitespiramycin is a group of 4''-O-acylated spiramycins with 4''-O-isovalerylspiramycins as the major components [&lt;ulink linkID="1772797" linkType="Reference"&gt;1772797&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1064862">Shenyang Tonglian Group Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2012-12-28T00:00:00.000Z</StatusDate><Source id="1384044" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1012170">Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2012-12-28T00:00:00.000Z</StatusDate><Source id="1384044" type="PR"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><OwnerCompany id="1064862">Shenyang Tonglian Group Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="40">Bacterial infection</Indication><AwardedIndication>Bacterial infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-09-03T00:00:00.000Z</MileStoneDate><Source id="1976493" type="OTHER"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1064862">Shenyang Tonglian Group Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="40">Bacterial infection</Indication><AwardedIndication>Bacterial infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-03-28T00:00:00.000Z</MileStoneDate><Source id="2017900" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1012170">Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences</OwnerCompany><Country id="CN">China</Country><Indication id="40">Bacterial infection</Indication><AwardedIndication>Bacterial infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-03-28T00:00:00.000Z</MileStoneDate><Source id="2017900" type="CORPORATE"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2017900" linkType="reference" linkID="2017900"&gt;2017900&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1064862">Shenyang Tonglian Group Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1066199">Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="143300" title="Shenyang Tonglian Group to develop Institute of Medicinal Biotechnology's bitespiramycin"/></Deals><PatentFamilies><PatentFamily id="1745333" number="CN-01237976" title="Application spiramycin and that in the disease is"/><PatentFamily id="3177453" number="WO-2017114095" title="Applications of kelimycin in mycobacterium tuberculosis infection resistance"/><PatentFamily id="4324724" number="CN-108992416" title="A bitespiramycin tablet and preparation method thereof"/><PatentFamily id="435713" number="CN-101649325" title="A gene tandem technique for increasing main component content of gene engineering isovaleryl spiramycin"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenyang Tonglian Group Co Ltd" id="1064862"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Sciences &amp; Peking Union Medical College" id="1066199"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenyang Fuyang Pharmaceutical Technology Co Ltd" id="1153280"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Military Sciences" id="14168"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>